{"id":671400,"date":"2023-10-09T16:28:02","date_gmt":"2023-10-09T16:28:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=671400"},"modified":"2023-10-09T16:28:02","modified_gmt":"2023-10-09T16:28:02","slug":"gastric-cancer-pipeline-clinical-trials-studies-emerging-drugs-and-fda-approvals-2023-updated","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/gastric-cancer-pipeline-clinical-trials-studies-emerging-drugs-and-fda-approvals-2023-updated_671400.html","title":{"rendered":"Gastric Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, and FDA Approvals 2023 (Updated)"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1696840715.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Gastric Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, and FDA Approvals 2023 (Updated)\" src=\"https:\/\/www.abnewswire.com\/uploads\/1696840715.png\" alt=\"Gastric Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, and FDA Approvals 2023 (Updated)\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;Gastric Cancer Pipeline Insight 2023&rdquo; report provides comprehensive insights about 230+ companies and 230+ pipeline drugs in the Gastric Cancer pipeline landscape. It covers the Gastric Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastric Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Gastric Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s Gastric Cancer pipeline report depicts a robust space with 230+ active players working to develop 230+ pipeline therapies for Gastric Cancer treatment.<\/li>\n<li>The leading companies working in the Gastric Cancer Market include Hutchison Medipharma Limited, EMD Serono, Sumitomo Pharma, Jiangsu HengRui Medicine Co., Ltd., LintonPharm Co.,Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Eli Lilly and Company, Janssen Pharmaceutical K.K., Hoffmann-La Roche, Novartis, Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Merck Sharp &amp; Dohme LLC, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Merck KGaA, Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech, AB Science, Maxinovel, GlaxoSmithKline, Hoffmann-La Roche, Bayer, Hutchison Medipharma Limited, and others.<\/li>\n<li>Promising Gastric Cancer Pipeline Therapies in the various stages of development include S-1\/Cisplatin, FLX475, Pembrolizumab, Nivolumab, Oxaliplatin, Volitinib, Docetaxel, and others.<\/li>\n<li>September 2023: AstraZeneca announced a study of Phase 2 Clinical Trials for Capecitabine, Durvalumab, Oxaliplatin, Trastuzumab, and MEDI5752. The study will consist of 2 phases: a dose escalation phase (Part 1) and dose expansion phases (Part 2 and Part 3). Part 1 will enroll HER2-overexpressing (IHC 3+ or IHC 2+\/ISH+), previously treated gastric, gastro-esophageal junction (GEJ) or esophageal cancer patients, and Part 2 will enroll HER2-overexpressing patients who have not received prior treatment for metastatic or unresectable disease. Part 3 will enroll HER2-expressing patients who have not received prior treatment for metastatic or unresectable disease.<\/li>\n<li>September 2023: Ono Pharmaceuticals Co. Ltd announced a study of Phase 3 Clinical Trials ONO-4538, Ipilimumab, Oxaliplatin and Capecitabine. This study is to compare and evaluate the efficacy and safety of ONO-4538 in combination with ipilimumab and chemotherapy versus chemotherapy in chemotherapy-na&iuml;ve participants with HER2-negative unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer).<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in Gastric Cancer Treatment Drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/gastric-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Gastric Cancer Pipeline Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">In the Gastric Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gastric Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It&rsquo;s also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over. It is more common in men than women. Many stomach cancers are linked to lifestyle or environmental factors, including diet. Stomach cancer is linked with a bacteria that lives in the stomach called Helicobacter pylori.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Find out more about Gastric Cancer Therapeutics Assessment @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastric-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Gastric Cancer Preclinical and Discovery Stage Products<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Gastric Cancer Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>IBI308: Innovent Biologics<\/li>\n<li>HLX10: Henlix Biotech<\/li>\n<li>Pamiparib: BeiGene<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Gastric Cancer Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 230+ key companies which are developing the Gastric Cancer therapies. The Gastric Cancer companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the emerging Gastric Cancer Pipeline Therapies @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastric-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Gastric Cancer Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Gastric Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li>Gastric Cancer Companies- Hutchison Medipharma Limited, EMD Serono, Sumitomo Pharma, Jiangsu HengRui Medicine Co., Ltd., LintonPharm Co.,Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Eli Lilly and Company, Janssen Pharmaceutical K.K., Hoffmann-La Roche, Novartis, Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Merck Sharp &amp; Dohme LLC, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Merck KGaA, Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech, AB Science, Maxinovel, GlaxoSmithKline, Hoffmann-La Roche, Bayer, Hutchison Medipharma Limited, and others.<\/li>\n<li>Gastric Cancer Pipeline Therapies- S-1\/Cisplatin, FLX475, Pembrolizumab, Nivolumab, Oxaliplatin, Volitinib, Docetaxel, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for new drugs for Gastric Cancer Treatment, Visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastric-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Gastric Cancer Market Drivers and Barriers, and Future Perspective<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Gastric Cancer: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>IBI308: Innovent Biologics<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Pamiparib: BeiGene<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>HC 5404 FU: HiberCell<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>PolyPEPI 1311: Treos Bio<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Gastric Cancer Key Companies<\/li>\n<li>Gastric Cancer Key Products<\/li>\n<li>Gastric Cancer- Unmet Needs<\/li>\n<li>Gastric Cancer- Market Drivers and Barriers<\/li>\n<li>Gastric Cancer- Future Perspectives and Conclusion<\/li>\n<li>Gastric Cancer Analyst Views<\/li>\n<li>Gastric Cancer Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information on the Gastric Cancer Pipeline therapeutics, reach out to <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastric-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Gastric Cancer Unmet Needs and Analyst Views<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=gastric-cancer-pipeline-clinical-trials-studies-emerging-drugs-and-fda-approvals-2023-updated\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/ci-tracking\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/ci-tracking<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/ci-tracking\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=gastric-cancer-pipeline-clinical-trials-studies-emerging-drugs-and-fda-approvals-2023-updated\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;Gastric Cancer Pipeline Insight 2023&rdquo; report provides comprehensive insights about 230+ companies and 230+ pipeline drugs in the Gastric Cancer pipeline landscape. It covers the Gastric Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/gastric-cancer-pipeline-clinical-trials-studies-emerging-drugs-and-fda-approvals-2023-updated_671400.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-671400","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/671400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=671400"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/671400\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=671400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=671400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=671400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}